NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-DK-20-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites institutional career development program (K12) applications in the area of epidemiology of benign urological conditions. This institutional program will provide scholars with research and/or clinical doctoral degrees (including MD, PhD, MD/PhD, DrPH) with the skills and resources necessary to initiate an independent research career in the epidemiology of benign urological conditions within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.
Funding Opportunity PAR-20-120 from the NIH Guide for Grants and Contracts. The purpose of the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) Funding Opportunity Announcement (FOA) is to facilitate the translation of vaccine candidates into early clinical testing. The IPCAVD program is designed to enable a multi-disciplinary team to complete necessary steps from final down-selection of an advanced vaccine candidate through regulatory submissions needed for clinical trial(s). These steps include technology transfer, process development, optimization, assay development and qualification, analytical testing, cGMP manufacture, quality assurance oversight, safety testing, product release, drug substance and drug product stability testing program, IND-enabling studies, and regulatory submissions. This FOA will not provide funds for conducting the clinical studies; applicants are encouraged to collaborate with NIAID-supported clinical trial networks or to develop other relationships to support the clinical studies.
Notice NOT-OD-20-073 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-20-111 from the NIH Guide for Grants and Contracts. Reissue of PAR-18-541. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.
Funding Opportunity PAR-20-122 from the NIH Guide for Grants and Contracts. Reissue of PAR-18-546. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.
Notice NOT-DK-20-014 from the NIH Guide for Grants and Contracts
Notice NOT-AG-20-020 from the NIH Guide for Grants and Contracts
Notice NOT-AR-20-009 from the NIH Guide for Grants and Contracts
Notice NOT-CA-20-033 from the NIH Guide for Grants and Contracts
Notice NOT-GM-20-024 from the NIH Guide for Grants and Contracts
Notice NOT-AI-20-038 from the NIH Guide for Grants and Contracts
Notice NOT-AG-20-019 from the NIH Guide for Grants and Contracts
Notice NOT-AG-20-018 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-075 from the NIH Guide for Grants and Contracts
Notice NOT-TR-20-006 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-074 from the NIH Guide for Grants and Contracts
Notice NOT-DK-20-013 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-076 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-20-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support development of promising universal influenza vaccine candidates that protect against both influenza A and B viruses.
Notice NOT-CA-20-014 from the NIH Guide for Grants and Contracts